

Steen Dalby Kristensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2447991/publications.pdf>

Version: 2024-02-01

91
papers

12,827
citations

147801

31
h-index

48315

88
g-index

93
all docs

93
docs citations

93
times ranked

15454
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA as Biomarkers for Platelet Function and Maturity in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 181-195.	3.4	13
2	Cardiovascular risks associated with smoking in patients without obstructive coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e14-e17.	1.8	0
3	Association of whole blood microRNA expression with platelet function and turnover in patients with coronary artery disease. <i>Thrombosis Research</i> , 2022, 211, 98-105.	1.7	7
4	Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	1.7	0
5	Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100301.	5.6	6
6	Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, , .	2.7	2
7	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS ₂ -P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	2.2	8
8	Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia. <i>British Journal of Haematology</i> , 2022, 198, 693-702.	2.5	3
9	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	1.5	53
10	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021, 136, 106809.	2.1	5
11	Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular biomarkers in heart transplant recipients: An exploratory study. <i>Clinical Transplantation</i> , 2021, 35, e14133.	1.6	6
12	Immature Platelets and Risk of Cardiovascular Events among Patients with Ischemic Heart Disease: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2021, 121, 659-675.	3.4	16
13	The ACVC transatlantic collaboration: an initiative for exchange of knowledge and science. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 234-235.	1.0	0
14	Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease. <i>TH Open</i> , 2021, 05, e230-e238.	1.4	4
15	Statistical and machine learning methods for analysis of multiplex protein data from a novel proximity extension assay in patients with ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2021, 11, 13787.	3.3	1
16	Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 160, 14-20.	1.6	2
17	CHA ₂ DS ₂ -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, , e13717.	3.4	0
18	Smoking is the dominating modifiable risk factor in younger patients with STEMI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 70-75.	1.0	9

#	ARTICLE	IF	CITATIONS
19	Benefits and Harm of Treatment with P2Y12 Inhibitors beyond 12 Months in Patients with Coronary Artery Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 446-456.	2.7	2
20	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). <i>American Journal of Cardiology</i> , 2020, 125, 349-353.	1.6	5
21	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020, 131, 40-48.	1.6	7
22	Agreement between nonculprit stenosis follow-up iFR and FFR after STEMI (iSTEMI substudy). <i>BMC Research Notes</i> , 2020, 13, 410.	1.4	4
23	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 2052-2063.	1.6	48
24	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1248-1256.	3.4	7
25	Instantaneous wave-free ratio cutoff values for nonculprit stenosis classification in patients with ST-segment elevation myocardial infarction (an iSTEMI substudy). <i>Coronary Artery Disease</i> , 2020, 31, 411-416.	0.7	1
26	Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 22-27.	4.0	12
27	Quantitative flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation myocardial infarction—An iSTEMI substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 686-692.	1.7	45
28	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	3.0	12
29	The ABO locus is associated with increased platelet aggregation in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2019, 286, 152-158.	1.7	8
30	Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 624-633.	2.9	27
31	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158.	1.6	10
32	Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 567-573.	1.7	11
33	Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. <i>Platelets</i> , 2019, 30, 322-328.	2.3	14
34	The year in cardiology 2017: coronary interventions. <i>European Heart Journal</i> , 2018, 39, 914-924.	2.2	1
35	Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007107.	2.6	157
36	Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 405-414.	1.2	45

#	ARTICLE	IF	CITATIONS
37	Coronary stent implantation and adverse cardiac events after surgery. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13030.	3.4	3
38	Neutrophil gelatinase-associated lipocalin (NGAL) and cardiovascular events in patients with stable coronary artery disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 470-476.	1.2	13
39	Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction. <i>Thrombosis Research</i> , 2018, 172, 21-28.	1.7	17
40	Effect of remote ischaemic conditioning on platelet aggregation and platelet turnover. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 528-533.	2.1	4
41	Platelet characteristics in patients with essential thrombocytosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 918-927.	1.5	33
42	Fibrin clot lysis assay: Establishment of a reference interval. <i>Thrombosis Research</i> , 2018, 167, 9-11.	1.7	16
43	Thrombopoietin and platelet aggregation in patients with stable coronary artery disease. <i>Platelets</i> , 2017, 28, 822-824.	2.3	1
44	A genetic risk score predicts cardiovascular events in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2017, 241, 411-416.	1.7	16
45	Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	14
46	Nonculprit Stenosis Evaluation Using Instantaneous Wave-Free Ratio in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2528-2535.	2.9	55
47	Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. <i>American Journal of Case Reports</i> , 2017, 18, 945-948.	0.8	9
48	Coronary artery disease-associated genetic variants and biomarkers of inflammation. <i>PLoS ONE</i> , 2017, 12, e0180365.	2.5	25
49	Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2622-2632.	2.8	89
50	Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. <i>Endoscopy International Open</i> , 2016, 04, E527-E533.	1.8	5
51	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	104
52	Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. <i>Open Heart</i> , 2016, 3, e000427.	2.3	6
53	Effect of remote ischaemic conditioning on coagulation and fibrinolysis. <i>Thrombosis Research</i> , 2016, 141, 129-135.	1.7	13
54	Platelets and Antiplatelet Therapy in Patients with Coronary Artery Disease and Diabetes. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 234-241.	2.7	25

#	ARTICLE	IF	CITATIONS
55	The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2015, 114, 519-529.	3.4	28
56	The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. <i>PLoS ONE</i> , 2015, 10, e0132629.	2.5	15
57	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	13.7	107
58	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2133-2147.	1.8	30
59	Reduced Effect of Aspirin and Clopidogrel Following Hybrid Coronary Revascularization. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 603-611.	1.7	3
60	Accidentally crushed stent during complex bifurcation treatment. A potential cause of very late stent thrombosis. <i>International Journal of Cardiology</i> , 2015, 197, 113-115.	1.7	7
61	Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?. <i>Vascular Pharmacology</i> , 2015, 73, 8-10.	2.1	2
62	Calprotectin and Platelet Aggregation in Patients with Stable Coronary Artery Disease. <i>PLoS ONE</i> , 2015, 10, e0125992.	2.5	17
63	Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease. <i>PLoS ONE</i> , 2015, 10, e0126767.	2.5	37
64	Platelet Turnover in Stable Coronary Artery Disease – Influence of Thrombopoietin and Low-Grade Inflammation. <i>PLoS ONE</i> , 2014, 9, e85566.	2.5	50
65	Impact of Health Care System Delay in Patients With ST-Elevation Myocardial Infarction on Return to Labor Market and Work Retirement. <i>American Journal of Cardiology</i> , 2014, 114, 1810-1816.	1.6	25
66	Rapid evaluation of platelet function using the Multiplate® Analyzer. <i>Platelets</i> , 2014, 25, 628-633.	2.3	43
67	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2014, 383, 2047-2056.	13.7	96
68	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014, 168, 622-631.e2.	2.7	16
69	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. <i>American Heart Journal</i> , 2014, 168, 611-621.	2.7	34
70	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. <i>Thrombosis Research</i> , 2014, 133, 1161-1163.	1.7	5
71	Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1. <i>PLoS ONE</i> , 2014, 9, e111816.	2.5	39
72	Increased platelet aggregation and turnover in the acute phase of ST-elevation myocardial infarction. <i>Platelets</i> , 2013, 24, 528-537.	2.3	27

#	ARTICLE	IF	CITATIONS
73	Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2013, 109, 920-929.	3.4	27
74	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.2	3,915
75	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. <i>PLoS ONE</i> , 2013, 8, e71150.	2.5	32
76	Pharmacogenetics of the Antiplatelet Effect of Aspirin. <i>Current Pharmaceutical Design</i> , 2012, 18, 5294-5308.	1.9	37
77	Contemporary use of glycoprotein IIb/IIIa inhibitors. <i>Thrombosis and Haemostasis</i> , 2012, 107, 215-224.	3.4	54
78	Platelet aggregation is dependent on platelet count in patients with coronary artery disease. <i>Thrombosis Research</i> , 2012, 129, 56-61.	1.7	100
79	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	2.8	257
80	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	2.2	3,144
81	Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012, 108, 140-147.	3.4	17
82	Implementation of primary angioplasty in Europe: Stent for Life initiative progress report. <i>EuroIntervention</i> , 2012, 8, 35-42.	3.2	45
83	Increased Inflammatory Markers in Patients with Reduced Antiplatelet Effect of Aspirin.. <i>Blood</i> , 2012, 120, 2252-2252.	1.4	0
84	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	2.2	203
85	A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1245-1253.	3.4	125
86	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. <i>Lancet, The</i> , 2010, 375, 1090-1099.	13.7	198
87	Immature platelets in patients with acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2009, 101, 151-153.	3.4	171
88	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
89	Magnesium Inhibits Platelet Activity - an Infusion Study in Healthy Volunteers. <i>Thrombosis and Haemostasis</i> , 1996, 75, 939-944.	3.4	52
90	Magnesium Inhibits Platelet Activity - An In Vitro Study. <i>Thrombosis and Haemostasis</i> , 1996, 76, 088-093.	3.4	39

#	ARTICLE	IF	CITATIONS
91	Platelet Number and Volume during Myocardial Infarction in Relation to Infarct Size. Acta Medica Scandinavica, 1986, 220, 401-405.	0.0	32